-
Can GenAI for Literature Reviews Ever Be Trusted? A Pragmatic Approach That’s Ethically Designed and Purpose-built for HEOR Professionals
-
Conducting Research and Survey Studies in Hard-to-Reach Populations
-
Patient Involvement in Value and Health Technology Assessment (V/HTA)
-
Global Perspective on Inequality Aversion: Methods and Learnings
-
Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?
-
October 16-17: Applying RWD and Novel Data Sources to Advance Patient-Centric Health Equity, Outcomes, and Economic Evaluations- Virtual
-
IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings
-
The Burden of Time: MS Treatment and Socio-Economic Impact Reduction
-
November 17: Introduction to Applied Generative AI for HEOR - In Person at ISPOR Europe 2024
-
November 17: Developing Decision-Grade Real-World Evidence - In Person at ISPOR Europe 2024
-
November 17: Reimbursement Systems for Pharmaceuticals in Europe - In Person at ISPOR Europe 2024
-
November 17: Valuation of Innovative Drugs - In Person at ISPOR Europe 2024
-
November 17: Core Concepts and Approaches to Early-Stage Health Technology Assessment - In Person at ISPOR Europe 2024
-
November 17: Health Economic Modeling in R: A Hands-on Introduction - In Person at ISPOR Europe 2024
-
November 17: Causal Inference and Causal Estimands From Target Trial Emulations Using Evidence from Real-World Observational Studies and Clinical Trials - In Person at ISPOR Europe 2024
-
November 17: Introduction to Health Economics and Outcomes Research - In Person at ISPOR Europe 2024
-
November 17: Real-World Evidence in External Control Arms: Driving Innovation in Drug Development - In Person at ISPOR Europe 2024
-
November 17: Applied Cost-Effectiveness Modeling with R - In Person at ISPOR Europe 2024
-
November 17: Advanced Patient-Reported Outcomes - In Person at ISPOR Europe 2024
-
November 17: Introduction to Machine Learning Methods - In Person at ISPOR Europe 2024